Skip to main content

Talasaz AmirAli's Form 4 filing

Guardant Health, Inc. (GH) · filed Nov 23, 2021

Accession no.
0001576280-21-000108
Filed
Nov 23, 2021
Trade date
Nov 19-23, 2021
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions. Open-market purchases total $10.0M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Talasaz AmirAliCIK 0001753159Director, Officer (Co-Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 19, 2021COMMON STOCKPPurchaseAcquired+37,721$97.82F1+$3,689,868.221,787,066Direct
Nov 19, 2021COMMON STOCKPPurchaseAcquired+12,279$98.78F2+$1,212,919.621,799,345Direct
Nov 23, 2021COMMON STOCKPPurchaseAcquired+6,033$92.42F3+$557,569.861,805,378Direct
Nov 23, 2021COMMON STOCKPPurchaseAcquired+23,467$93.05F4+$2,183,604.351,828,845Direct
Nov 23, 2021COMMON STOCKPPurchaseAcquired+5,000$94.00+$470,0001,833,845Direct
Nov 23, 2021COMMON STOCKPPurchaseAcquired+5,000$95.50+$477,5001,838,845Direct
Nov 23, 2021COMMON STOCKPPurchaseAcquired+14,900$96.83F5+$1,442,7671,853,745Direct
Nov 23, 2021COMMON STOCKPPurchaseAcquired+100$98.00+$9,8001,853,845Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $97.64 to $98.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F2

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $98.75 to $99.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $91.885 to $92.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $92.915 to $93.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $96.50 to $97.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)